Intravenous treatment adherence of patients with chronic inflammatory rheumatic diseases during the COVID-19 pandemic: experience of a single center

Publicado en línea: 22 sept 2022

Páginas: 173 - 181

Recibido: 28 abr 2022

DOI: https://doi.org/10.2478/rjim-2022-0010

Palabras clave

coronavirus, infliximab, intravenous infusion, patient adherence, rheumatology, rituximab

© 2022 Hatice Ecem Konak et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.